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RESEARCH ON METHODS – Study Design
PRM51
COMPREHENSIVE REVIEW OF EMPLOYER-SPONSORED WELLNESS STRATEGIES
AND THEIR ECONOMIC AND HEALTH-RELATED OUTCOMES: EVIDENCE
QUALITY AND OPPORTUNITIES FOR FUTURE RESEARCH
Kaspin LC1, Gorman KM1, Miller RM2
1Cerner LifeSciences Consulting, Beverly Hills, CA, USA, 2Cerner Health Connect, Beverly Hills,
CA, USA
OBJECTIVES: A rising number of companies are sponsoring wellness programs to
improve employee health and reduce health care costs. This review sought to
determine the characteristics and outcomes of employer-sponsored wellness pro-
grams and determine possible reasons for their success. METHODS: PubMed, ABI
Inform, and Business Source Premier databases and Corporate Wellness Magazine
were searched. English-language articles published from 2005-2011 reporting char-
acteristics of employer-sponsored wellness programs and their impact on health-
related and economic outcomes amongUS employeeswere accepted. Animal stud-
ies, non-US-based studies, letters, editorials, and economic models were not
accepted. Data were abstracted, synthesized, and interpreted. RESULTS: Twenty
references were accepted. Wellness interventions were classified into health as-
sessments, lifestyle management, and behavioral health. While improved eco-
nomic outcomes were reported for companies with wellness programs (ie, total
health care costs, return on investment, absenteeism, productivity, workers’ com-
pensation, utilization) as well as decreased health risks, cause-and-effect relation-
ships could not be determined. Fourteen accepted articles were published in mag-
azines and four in newspapers. Only three were published in peer-reviewed
journals and those articles were the only ones to report a study design: 2 were
described as quasi-experimental and the third a survey. Most articles described
one company’s wellness programs and outcomes, with some reporting changes
over time. Some of the reported wellness programs were not described in full
detail. Multiple types of outcomes were described across accepted articles, which
precluded comparisons of an individual outcome across studies. Some articles
described multiple interventions, making it difficult to assess benefits from indi-
vidual interventions. CONCLUSIONS: While employer-sponsored wellness pro-
grams are being reported along with improved outcomes, there are limited defin-
itive data on a cause-and-effect relationship. Further research, of a high
methodological caliber, is needed to support informed decisions. Specifically, ran-
domized trials and economic analyses would empower employers with the infor-
mation needed to implement successful wellness programs.
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SYSTEMATIC REVIEW OF GUIDELINE RECOMMENDATIONS ON COMPARATOR
SELECTION IN HEALTH ECONOMIC EVALUATIONS
Wagner M, Melnyk P, Rindress D
BioMedCom Consultants Inc., Dorval, QC, Canada
OBJECTIVES: Choice of comparator(s) is a critical design parameter for any health
economic evaluation (HE). HE guidelines may differ in their recommendations on
this issue. We reviewed all accessible HE guidelines to identify shared themes and
differences within their recommendations on comparator selection. METHODS:
We systematically searched PubMed/Medline, the Centre for Reviews and Dissem-
ination, the EQUATOR network, and websites of health technology assessment
agencies andhealthcare coverage decisionmaking bodies for publicly accessible HE
guidelines. Guidelineswere classified as jurisdictional mandatory or non-mandatory or
as general. Following review and parsing, data was extracted into a template and
recommendations were coded under common, non-mutually exclusive themes.
Both qualitative and quantitative analyses were performed. RESULTS: Seventy-
four HE guidelineswere identified and reviewed, of which 74%mentioned the issue
of comparators: 96% of jurisdictional mandatory, 91% of jurisdictional non-man-
datory and 58% of general guidelines. The most frequent recommendations with
respect to comparator selection were to use themost common treatment (70.9% of
all guidelines), to include “no intervention” when appropriate (41.8%), and to use
best practice (e.g., guideline-or specialist recommended treatment) as comparator
(29.1%). Other recommendations were to compare with the treatment most likely
to be replaced (18.2%), to use all alternative treatments (16.4%), and the least costly
treatment (14.5%). Almost half (45.5%) of guidelines specified justification of choice
of comparator and 21.8% detailed description of all comparators. Mandatory juris-
dictional guidelines weremore likely than general guidelines to specify most com-
mon treatment (86.4% vs. 47.8%, P0.01 Fisher’s exact test), whereas general guide-
lines were more likely to recommend all alternative forms of therapy (30.4% vs.
4.5%, P0.05). CONCLUSIONS: Although there are common themes among guide-
lines on comparator selection, differences exist of whichmodel developers need to
be aware.
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SOURCE DATA VERIFICATION IN OBSERVATIONAL STUDIES: REVIEW OF
CURRENT PRACTICE
Velthuis EJ1, Richards MS2, Malka ES2
1PPD, Bennekom, The Netherlands, 2PPD, Morrisville, NC, USA
OBJECTIVES: Post-approval product research in the form of observational study is
increasingly prominent. Observational studies inform real-world safety and effec-
tiveness. Lack of specific regulatory requirements or guidances for source data
verification (SDV) in these studies, however, leaves sponsors and partner CROs to
determine the level of SDV necessary to ensure quality. A literature review was
performed to determine the level of SDV in practice in published observational
studies. METHODS: Google Scholar and Pubmed searches were used to retrieve
relevant publications. The term ‘source data verification’ was used in combination
with the terms ‘observational study’ and ‘non-interventional study’. Articles read-
ily available in full text were included for analysis. The methods sections were
screened to determine the level of SDV applied. If multiple publications referred to
a single study or registry, only one representative publication was selected for
inclusion. RESULTS: Of the observational studies included, 37 studies mentioned
SDV in their methods section. Of these, 16 (43%) did not further specify the level of
SDV. In the remaining 21 studies, SDV ranged from0 to 100%,with amedian of 10%.
Subject numbers in these 21 studies ranged between 135 and 19,870 (median: 864.)
These studies were mainly prospective (14/21) and were conducted in the EU (16/
21), China (1/21), Australia (1/21), the Philippines (1/21) and worldwide (2/21). The
majority (16/21) of the studies were reported to be funded by the pharmaceutical
industry. Generally, studies larger than 1000 subjects sought to verify data sources
for only 10% of their population. CONCLUSIONS: The level of SDV is not routinely
specified in themethods section of observational study publications. In those pub-
lications that did elaborate on study quality, the level of SDV ranges between 0%
and 100%,with large (n1000 subjects) observational studies restricting the level of
SDV to a maximum of 10%.
RESEARCH ON METHODS – Conceptual Papers
PRM54
A CONCEPTUAL ANALYSIS OF WHEN MEDICAL EXPENDITURE PANEL SURVEY
(MEPS) MEETS COST OF ILLNESS (COI) – ARE THEY A MATCH?
Coughlan D, Frick KD
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
OBJECTIVES:MEPS has been used as a data source for many direct medical expen-
ditures (DME)/COI type studies. The objective of this conceptual analysis is to re-
view the literature & evaluate the 4 main COI type studies with reference to pa-
tients with head and neck cancer (HNC) using the MEPS data source. METHODS:
The 4main COI methods are 1) Sum_All Medical; 2) Sum_Diagnosis Specific; and 3)
Matched Control (iv) Regression. Without a comparison group, analysts use a total
cost approach. With a comparison group, an incremental cost approach is most
often reported. ISPOR does not have standard guidelines in reporting COI studies;
analysts often vary in their perspective, but should alwaysmake reference tomed-
ical costs, morbidity & mortality costs, transportation/nonmedical costs and pro-
ductivity losses in their analysis. RESULTS: A review of recent COI type papers
(n10) that have usedMEPS shows that analysts report findings based on usually 1
COI method. Only 2 studies (COPD & Diabetes) reported both total and incremental
cost approaches in their analysis. Four studies merged condition, event and con-
solidated year files, which allows diagnosis specific estimates to be produced. As a
conceptual analysis, HNC is used to illustrate that MEPS facilitates analysts to use
the 4 main COI methods especially if DME is the outcome of interest.
CONCLUSIONS:MEPS is a valuable and utilized national resource. It is possible that
“good practice guidelines” can be developed (& perhaps endorsed by AHRQ) for
those using MEPS to report a DME/COI type study. By using & reporting all 4 meth-
ods, an analyst is giving policy-makers a range for their cost estimates. Guidelines
would ensure a level of transparency in reporting such cost estimates across con-
ditions.
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MODELING THE PROGRESSION OF CHRONIC DISEASES IN A DYNAMIC MARKET:
IMPLICATIONS FOR BUDGET IMPACT ANALYSIS
Eldar-Lissai A1, Banerjee R1, Mcbride S2, Leaf-herrmann W1
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The ISPOR task force guidelines on good research practices for Budget Impact Anal-
yses (BIA) identify two simultaneous processes affecting themarketplace: changes
in the mix and evolution of available interventions over time (i.e., market share)
and changes in the target population resulting from various disease characteristics
(e.g., incidence, progression and death). Inmany chronic diseases, disease severity
changes over time and thus medical costs vary across disease cohorts. Hence, in a
budget impact model two constraints must be met: 1) the number of patients
progressing from one year to the next corresponds to known disease statistics (i.e.,
patients who enter the model cannot be ‘lost to follow-up’), 2) the total number of
treated patients conforms with known population size and projected market
shares. The current guidelines lack detail on how to satisfy these two constraints
simultaneously in dynamicmarkets with non-trivial rates of patient attrition from
treatment groups. OBJECTIVES: To identify a method that allows researchers to
more accurately model the budget impact of new interventions for chronic dis-
eases in dynamic markets. METHODS: We propose a simple adjustment factor
which is a function of disease and treatment’s attrition rate in two consecutive
years to correct the allocation of patients across disease cohorts such that the two
constraints identified above are always met simultaneously. We compare two set-
tings (static vs. dynamic markets) and analyze the implications over a time period
of five years. RESULTS: We find that applying the adjustment factor in dynamic
markets reduces the bias in budget impact measures by 15% or more and contend
that not correcting for this inmore complexmarkets would lead to higher bias. Our
proposed solution is a simple way of accounting for differential rates of attrition
across treatments in a chronic disease setting in budget impact analyses.
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COST-EFFECTIVENESS ANALYSIS IN PERSONALIZED MEDICINE: GENERAL
HYPOTHESES AND CORRESPONDING DECISION TREE STRUCTURES FOR
SCREENING, DIAGNOSTIC, PREDICTIVE, PROGNOSTIC, SURVEILLANCE, AND
MONITORING TESTS
Mladsi DM, Herring WL, Earnshaw SR
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